Audentes Therapeutics (BOLD) Rating Increased to Hold at Zacks Investment Research

Audentes Therapeutics (NASDAQ:BOLD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “

A number of other equities analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Audentes Therapeutics in a research report on Wednesday. Raymond James Financial reiterated a “hold” rating on shares of Audentes Therapeutics in a research report on Thursday, January 4th. BMO Capital Markets set a $44.00 price objective on shares of Audentes Therapeutics and gave the company a “buy” rating in a research report on Friday, January 5th. William Blair restated a “buy” rating on shares of Audentes Therapeutics in a research report on Friday, January 5th. Finally, Wedbush raised their price objective on shares of Audentes Therapeutics to $56.00 and gave the company an “outperform” rating in a research report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $35.00.

Shares of Audentes Therapeutics (BOLD) traded down $0.05 during trading hours on Friday, reaching $31.33. 439,674 shares of the company’s stock were exchanged, compared to its average volume of 588,228. The company has a market capitalization of $1,209.29, a price-to-earnings ratio of -8.98 and a beta of 0.41. Audentes Therapeutics has a 12-month low of $13.90 and a 12-month high of $41.80.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.88). analysts anticipate that Audentes Therapeutics will post -3.5 earnings per share for the current fiscal year.

In other Audentes Therapeutics news, Director Louis G. Lange sold 18,000 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total transaction of $555,840.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. Insiders sold 36,000 shares of company stock valued at $1,052,480 over the last 90 days. 47.30% of the stock is owned by company insiders.

A number of institutional investors have recently made changes to their positions in the business. Virtus Fund Advisers LLC bought a new stake in Audentes Therapeutics during the fourth quarter valued at approximately $372,000. BlackRock Inc. lifted its position in Audentes Therapeutics by 13.2% during the fourth quarter. BlackRock Inc. now owns 1,358,498 shares of the biotechnology company’s stock valued at $42,452,000 after purchasing an additional 158,576 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Audentes Therapeutics by 50.6% during the fourth quarter. Bank of New York Mellon Corp now owns 82,409 shares of the biotechnology company’s stock valued at $2,575,000 after purchasing an additional 27,687 shares during the last quarter. Wells Fargo & Company MN lifted its position in Audentes Therapeutics by 136.1% during the fourth quarter. Wells Fargo & Company MN now owns 34,026 shares of the biotechnology company’s stock valued at $1,063,000 after purchasing an additional 19,612 shares during the last quarter. Finally, Swiss National Bank bought a new stake in Audentes Therapeutics during the fourth quarter valued at approximately $1,038,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/09/audentes-therapeutics-bold-rating-increased-to-hold-at-zacks-investment-research.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply